ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next
December 15, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX) is back on investors’ radar today as fresh coverage and new analysis dig into a major European regulatory milestone for its lead therapy ANKTIVA (nogapendekin alfa inbakicept). The market’s obsession is simple: